LYTICON, LLC

Biotech · Private

F12, a deimmunized engineered lysostaphin enzyme therapeutic for methicillin-resistant Staphylococcus aureus (MRSA) infections

Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Design and Development of Immunotolerant S. aureus Biotherapies$868,526
Federal grantDepartment of Health and Human Services · Phase II · Design and Development of Immunotolerant S. aureus Biotherapies$609,888
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1118FGF Therapeutics INC.——
1119DURAVAX INC——
1120XGENOMES CORP.——
1121LYTICON, LLC——
1122Sana Biotechnology—$867M
1123Walden Biosciences——
1124Kriya Therapeutics—$769M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.